- Home
- CRTO vs ZLAB Comparison
CRTO vs ZLAB Comparison
Compare CRTO & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRTO
- ZLAB
- Stock Information
- Founded
- CRTO 2005
- ZLAB 2013
- Country
- CRTO France
- ZLAB China
- Employees
- CRTO N/A
- ZLAB N/A
- Industry
- CRTO Advertising
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- CRTO Consumer Discretionary
- ZLAB Health Care
- Exchange
- CRTO Nasdaq
- ZLAB Nasdaq
- Market Cap
- CRTO 1.4B
- ZLAB 3.6B
- IPO Year
- CRTO 2013
- ZLAB 2017
- Fundamental
- Price
- CRTO $24.84
- ZLAB $35.48
- Analyst Decision
- CRTO Buy
- ZLAB Buy
- Analyst Count
- CRTO 11
- ZLAB 5
- Target Price
- CRTO $44.70
- ZLAB $54.28
- AVG Volume (30 Days)
- CRTO 439.9K
- ZLAB 852.9K
- Earning Date
- CRTO 07-31-2025
- ZLAB 08-05-2025
- Dividend Yield
- CRTO N/A
- ZLAB N/A
- EPS Growth
- CRTO 107.32
- ZLAB N/A
- EPS
- CRTO 2.44
- ZLAB N/A
- Revenue
- CRTO $1,934,668,000.00
- ZLAB $418,326,000.00
- Revenue This Year
- CRTO N/A
- ZLAB $44.07
- Revenue Next Year
- CRTO $1.96
- ZLAB $49.13
- P/E Ratio
- CRTO $10.19
- ZLAB N/A
- Revenue Growth
- CRTO N/A
- ZLAB 43.72
- 52 Week Low
- CRTO $23.24
- ZLAB $16.01
- 52 Week High
- CRTO $49.93
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- CRTO 46.37
- ZLAB 49.40
- Support Level
- CRTO $23.70
- ZLAB $34.79
- Resistance Level
- CRTO $25.37
- ZLAB $36.97
- Average True Range (ATR)
- CRTO 0.76
- ZLAB 1.20
- MACD
- CRTO 0.27
- ZLAB -0.43
- Stochastic Oscillator
- CRTO 75.12
- ZLAB 15.39
About CRTO Criteo S.A.
Criteo SA is an ad-tech company in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. It has two reportable segments: Retail Media and Performance Media. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.